Myfortic

Myfortic

mycophenolic acid

Manufacturer:

Novartis

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Mycophenolate Na
Indications/Uses
In combination w/ ciclosporin & corticosteroids for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants.
Dosage/Direction for Use
720 mg bid (total daily dose: 1,440 mg). Must be initiated & maintained by transplant specialists.
Administration
May be taken with or without food: Swallow whole, do not chew/crush.
Special Precautions
Increased risk of developing lymphomas & other malignancies, particularly of the skin. Oversuppression of immune system increases susceptibility to infection. Active severe GI disease. Perform CBC regularly to monitor neutropenia. Lactation.
Adverse Reactions
Viral, bacterial & fungal infections, leukopenia, hypocalcemia, hypokalemia, hyperuricemia, HTN/hypotension, diarrhea.
Drug Interactions
Azathioprine, live vaccines, aciclovir, & Mg- & Al(OH)3-containing antacids. Cholestyramine & drugs that interfere w/ enterohepatic circulation.
MIMS Class
Immunosuppressants
ATC Classification
L04AA06 - mycophenolic acid ; Belongs to the class of selective immunosuppressive agents. Used to induce immunosuppression.
Presentation/Packing
Form
Myfortic gastro-resistant cap 360 mg
Packing/Price
120's
Form
Myfortic gastro-resistant tab 180 mg
Packing/Price
120's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in